JonesResearch downgraded Y-mAbs Therapeutics (YMAB) to Hold from Buy after SERB Pharmaceuticals agreed to acquire Y-mAbs for $8.60 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Palantir reports Q2 beat, Caterpillar posts mixed results: Morning Buzz
- Y-mAbs Therapeutics downgraded to Neutral from Outperform at Wedbush
- Y-Mabs Therapeutics Announces Merger with SERB Pharmaceuticals
- Y mAbs Therapeutics trading resumes
- SERB to acquire Y-mAbs Therapeutics for $8.60 per share in cash